And then on the injectable side, I think theres going to be, without question, a long horizon of on and off availability, just given the demand
This is a significant advantage for women who cant or prefer not to use hormonal treatments
So when it comes to estrogen hormone replacement therapy, that is helping restore the insulin sensitizing effects of estrogen, we also know that estrogen HRT can improve lipid profiles and it can blunt the visceral fat accumulation that we typically see in menopause
However, analysts at Leerink were critical of the latter, saying that there were no significant increases in free fatty acids whereas free fatty acids decreased by 7.5 percent with pooled groups of tirzepatide in the Phase III SURMOUNT-1 trial. The analysts were referring to trial data for Eli Lillys Zepbound, which demonstrated a mean weight loss of 21.1 percent over 36 weeks in its trials involving nondiabetic patients with obesity or overweight, making MariTides results roughly on par with Zepbound, despite the difficulty of cross-trial comparisons
